Intelligence · Patent portfolio
United Therapeutics Europe Patents
Full USPTO pharma patent portfolio for United Therapeutics Europe — grant dates, expiration, and drug cross-links.
- Patents
- 3,720
- Expiring ≤24m
- 234
Quick answer
United Therapeutics Europe has 3,720 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 234 expire within 24 months — use filters for patent-cliff planning.
-
US 6803386
Prostacyclin derivative containing compositions and methods of using the same for the treatment of cancer
expired -
US 6800475
Isolation of a human retrovirus
expired -
US 6800454
Nucleic acid molecule encoding chemokine-like factor 1 (CKLF1)
expired -
US 6797276
Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
expired -
US 6797275
Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
expired -
US 6794174
Full-length infectious cDNA clones of tick borne flavivirus
expired -
US 6794188
Retrovirus vectors derived from avian sarcoma leukosis viruses permitting transfer of genes into mammalian cells and therapeutic uses thereof
expired -
US 6793927
Construction of Pasteurella haemolytica vaccines
expired -
US 6794498
Method of eliminating inhibitory/instability regions of mRNA
expired -
US 6790449
Methods for producing self-replicating infectious RSV particles comprising recombinant RSV genomes or antigenomes and the N, P, L, and M2 proteins
expired -
US 6790936
CAI resistance proteins and uses thereof
expired -
US 6787145
Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods and vaccines
expired -
US 6787333
Retrovirus isolated from humans
expired -
US 6780847
Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
expired -
US 6780413
Immunotoxin (mAB-RICIN) for the treatment of focal movement disorders
expired -
US 6780969
Synthetic peptide composition as immunogens for prevention of urinary tract infection
expired -
US 6780417
Transmission blocking immunogen from malaria
expired -
US 6773880
Streptococcus pneumoniale 37-kDa surface adhesion A protein
expired -
US 6770291
Liposome complexes for increased systemic delivery
expired -
US 6770479
Anthrax vaccine
expired -
US 6767546
Use of echinacea as a feed additive to enhance protection against coccidiosis
expired -
US 6765104
Transition metal complexes of n, n',n″trialkyl-cis-1,3,5-triaminocyclohexane and related compositions and methods of synthesis and use
expired -
US 6761911
Use of chlorate ion or preparations thereof for reduction of food borne pathogens
expired -
US 6756033
Method for delivering benzindene prostaglandins by inhalation
expired -
US 6756038
Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
expired -
US 6756201
Diagnostic methods and gene therapy using reagents derived from the human metastasis suppressor gene KAI1
expired -
US 6756399
Use of lipoxygenase inhibitors and PPAR ligands as anti-cancer therapeutic and intervention agents
expired -
US 6756518
Scar reduction
expired -
US 6753317
Dmt-Tic di- and tri-peptide derivatives and related compositions and methods of use
expired -
US 6749856
Mucosal cytotoxic T lymphocyte responses
expired -
US 6750254
Nitric oxide-releasing amidine—and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same
expired -
US 6747055
Water-soluble drugs and methods for their production
expired -
US 6743797
Methods for treating cardiac arrhythmia
expired -
US 6743577
Methods of using cyanovirins to inhibit viral infection
expired -
US 6743626
Artificial salivary gland
expired -
US 6737511
Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
expired -
US 6737251
Nucleotide and deduced amino acid sequences of tumor gene Int6
expired -
US 6734014
Methods and compositions for transforming dendritic cells and activating T cells
expired -
US 6730498
Production of functional proteins: balance of shear stress and gravity
expired -
US 6719978
Virus-like particles for the induction of autoantibodies
expired -
US 6716450
Enhancing protein activity through nanoencapsulation
expired -
US 6713446
Formulation of boronic acid compounds
expired -
US 6713066
Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
expired -
US 6713081
Ocular therapeutic agent delivery devices and methods for making and using such devices
expired -
US 6713301
Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
expired -
US 6713284
Bacterial superantigen vaccines
expired -
US 6713444
Buforin I as a specific inhibitor and therapeutic agent for botulinum toxin B and tetanus neurotoxins
expired -
US 6710166
41 kDa Cryptosporidium parvum oocyst wall protein
expired
Frequently asked questions
How many patents does United Therapeutics Europe have?
3,720 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do United Therapeutics Europe patents expire?
234 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory